After Amazon One Medical (AMZN) launched a GLP-1 management program, Citi noted that if a patient is already a One Medical subscriber, they can get a prescription through their One Medical primary care provider. However, if a patient is not a One Medical subscriber, they can access an “on demand” provider for as low as $29 per visit to renew a prescription, but the “big caveat” is this option is only available for renewals, not new prescriptions, and it seems patients are limited to two renewals per year. While this “theoretically could be a significant threat” to platforms that charge membership fees greater than $100 per month ex-medications, such as Hims, the on-demand option is “not a replacement for these platforms,” the analyst tells investors. Citi has a Neutral rating and $24 price target on Hims & Hers (HIMS) shares.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade AMZNPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Amazon One Medical introduces weight management program
- Amazon (AMZN) Steps Up Weight Loss Push, Knocks HIMS Stock Off the Scale
- Bullish flow in Hims and Hers Health with shares up 8.9%
- Hims & Hers Stock Rallies on FDA Peptide Review, Leerink Analyst Calls Move a “Clear Positive”
- Morning News Wrap-Up, 4/16/26: Today’s Biggest Stock Market Stories!